Richard N van Zyl-Smit
Overview
Explore the profile of Richard N van Zyl-Smit including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
41
Citations
1089
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Bardsley S, Criner G, Halpin D, Han M, Hanania N, Hill D, et al.
Respir Med
. 2022 Dec;
205:107040.
PMID: 36470149
Background: Smoking is the major risk factor for chronic obstructive pulmonary disease (COPD). In IMPACT, single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) triple therapy significantly reduced moderate/severe exacerbation rates and improved lung function...
12.
Wijsenbeek M, Moor C, Johannson K, Jackson P, Khor Y, Kondoh Y, et al.
Lancet Respir Med
. 2022 Oct;
11(1):97-110.
PMID: 36206780
The widespread use of smartphones and the internet has enabled self-monitoring and more hybrid-care models. The COVID-19 pandemic has further accelerated remote monitoring, including in the heterogenous and often vulnerable...
13.
Al-Moamary M, Kokturk N, Idrees M, Sen E, Juvelekian G, Abi Saleh W, et al.
Respir Med
. 2021 Oct;
189:106641.
PMID: 34649155
Chronic obstructive pulmonary disease (COPD) has a significant impact on healthcare systems and health-related quality of life. Increased prevalence of smoking is an important factor contributing to high burden of...
14.
Spies R, Potter M, Hollamby R, van der Walt S, Hohlfeld A, Ochodo E, et al.
Syst Rev
. 2021 Jul;
10(1):211.
PMID: 34315541
Background: Chronic obstructive pulmonary disease (COPD) is a major cause of years of life lost globally. Acute exacerbations of COPD (AECOPD) drive disease progression, reduce quality of life and are...
15.
van Zyl-Smit R, Richards G
Afr J Thorac Crit Care Med
. 2021 Jul;
25(3).
PMID: 34286256
No abstract available.
16.
van Zyl-Smit R, Krull M, Gessner C, Gon Y, Noga O, Richard A, et al.
Lancet Respir Med
. 2020 Jul;
8(10):987-999.
PMID: 32653075
Background: Fixed-dose combinations (FDCs) of inhaled corticosteroids (ICS) and long-acting β-adrenoceptor agonists (LABA) are considered safe and efficacious in asthma management. Most available FDCs require twice-daily dosing to achieve optimum...
17.
Kerstjens H, Maspero J, Chapman K, van Zyl-Smit R, Hosoe M, Tanase A, et al.
Lancet Respir Med
. 2020 Jul;
8(10):1000-1012.
PMID: 32653074
Background: Patients with asthma who are inadequately controlled on inhaled corticosteroid-long-acting β-adrenoceptor agonist (ICS-LABA) combinations might benefit from the addition of a long-acting muscarinic receptor antagonist. The aim of the...
18.
Allwood B, Maasdorp E, Kim G, Cooper C, Goldin J, van Zyl-Smit R, et al.
Int J Chron Obstruct Pulmon Dis
. 2020 Jun;
15:1039-1047.
PMID: 32494129
Background: Pulmonary tuberculosis (PTB) is associated with many forms of chronic lung disease including the development of chronic airflow obstruction (AFO). However, the nature, evolution and mechanisms responsible for the...
19.
van Zyl-Smit R, Richards G, Leone F
Lancet Respir Med
. 2020 May;
8(7):664-665.
PMID: 32464099
No abstract available.
20.
Beeh K, Kirsten A, Tanase A, Richard A, Cao W, Hederer B, et al.
Int J Chron Obstruct Pulmon Dis
. 2018 Dec;
13:3923-3936.
PMID: 30584293
Background And Purpose: Fixed-dose combinations of a long-acting beta agonist and an inhaled corticosteroid are more effective than the individual components in COPD. The primary study objective was to demonstrate...